#FTC warns drugmakers against improper patent filings
The Federal Trade Commission (FTC) is warning drug companies against improper patent filings, saying that they could potentially face legal action for doing so. The FTC issued a statement Thursday saying that brand drug manufacturers could be harming competition in the generic market by improperly listing patents in the Food and Drug Administration’s “Orange Book” — a…